about
Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.SKF95365 induces apoptosis and cell-cycle arrest by disturbing oncogenic Ca(2+) signaling in nasopharyngeal carcinoma cells.Reduced Expression of FADS1 Predicts Worse Prognosis in Non-Small-Cell Lung CancerHigh expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma.The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma.Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial.Intraperitoneal Perfusion Therapy of Endostar Combined with Platinum Chemotherapy for Malignant Serous Effusions: A Meta-analysis.APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysisShort-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel.Four-miRNA signature as a prognostic tool for lung adenocarcinoma.GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury.High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic AnalysisClinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis
P50
Q33415579-F8559011-8C8A-4550-9BF4-DB46CC275248Q36239983-1C9EC0D1-ADE4-47E2-8C7E-3B4C50FE1FA1Q37067991-F7C3C268-6420-4899-B8D2-F63CFD1B1E9BQ38713836-143D3AF8-87A8-4A6A-B63B-2099E6B5D6DBQ38714407-5111305F-AFEB-48E9-916B-49D9890F65F4Q38729844-1E4CF3A0-0828-4467-9A07-E8AD1746814BQ40129406-6C9C6F1A-9778-45EE-8F03-33172C2910C3Q41708684-ED5ABCF3-8033-4C3C-AE94-8F4A1A531521Q44531228-F76F201E-2B88-45FF-8A6D-C278AC10C27FQ47215380-933EF6E5-110E-4EF9-8964-81ACBB16997EQ49189683-9DC17DB5-74F1-4F9A-BCC7-AF775F95265CQ49292463-ADDA62E5-4004-4074-9693-4AB2C2D07216Q52649648-8CA6A34B-B6CA-494E-A571-E224CC415F42Q57821720-DB6721D9-5FD0-40D3-B745-D65DDF5EACD2Q90904380-FEDA2B6B-864D-4009-B4E5-AAD7C44A9F1D
P50
description
researcher ORCID ID = 0000-0001-8034-5946
@en
name
Yan Lin
@ast
Yan Lin
@en
Yan Lin
@es
Yan Lin
@nl
type
label
Yan Lin
@ast
Yan Lin
@en
Yan Lin
@es
Yan Lin
@nl
prefLabel
Yan Lin
@ast
Yan Lin
@en
Yan Lin
@es
Yan Lin
@nl
P31
P496
0000-0001-8034-5946